Browse by Hotbed/Location
Filter News
Found 726,175 articles
-
Omnicell to Present at the Piper Sandler 35th Annual Healthcare Conference
11/27/2023
Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 1:00 p.m. ET.
-
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
1/4/2024
Innate Pharma SA announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on the lacutamab IND.
-
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
1/4/2024
Innate Pharma SA announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
-
Burning Rock Announces Receipt of Notification from NASDAQ - Jan 04, 2024
1/4/2024
Burning Rock Biotech Limited announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares was below the minimum bid price of US$1.00 per share requirement set forth in NASDAQ Listing Rule 5450.
-
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
1/4/2024
Laekna announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah.
-
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
1/4/2024
Longboard Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share.
-
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
1/4/2024
Keros Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of $40.00 per share.
-
SELLAS Life Sciences Announces Proposed Public Offering - Jan 04, 2024
1/4/2024
SELLAS Life Sciences Group, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in a public offering.
-
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
1/4/2024
Kuros Biosciences announced three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a real world patient population in the challenging posterolateral fusion procedure, and two 510 clearances from the U.S. Food and Drug Administration related to its MagnetOs family of products.
-
Angle PLC Announces Breakthrough Clinical Results
1/4/2024
ANGLE plc is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression of each patient's cancer and how this may be treated.
-
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
1/4/2024
Sitryx Therapeutics announces that Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
-
Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss BioSpace's tenth annual NextGen list of the hottest new life sciences companies.
-
Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Asensus Surgical, Inc. announced that the management team will participate and present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 3:00pm EST.
-
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Karyopharm Therapeutics Inc. announced that the Company's senior management team will participate at the 42nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.
-
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Editas Medicine, Inc., a clinical-stage genome editing company, announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.
-
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
1/3/2024
SELLAS Life Sciences Group, Inc. provided a business update and will host a corporate webinar at 8:30 am ET.
-
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
-
Entrada Therapeutics Promotes Nathan J. Dowden to President
1/3/2024
Entrada Therapeutics, Inc. announced that Nathan J. Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.
-
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
1/3/2024
Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that it is growing its distribution network by entering into an agreement with Walgreen Co. to distribute YCANTH™ through its specialty pharmacy.
-
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
1/3/2024
Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024.